Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Goyal

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2024
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profilingL Goyal, D DiToro, A Hollebecque, et al.
Acta Endocrinologica (Bucharest, Romania : 2005)|February 15, 2024
PHEOCHROMOCYTOMA, THE GREAT MASQUERADER, PRESENTING AS REVERSIBLE CARDIOMYOPATHY: <i>PRIMUM NON NOCERE</i>H Boro, H Sharma, D Mittal, et al.
ESMO Open|March 18, 2026
Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301G K Abou-Alfa, I Borbath, S Roychowdhury, et al.
British Journal of Cancer|June 25, 2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancerA F Hezel, M S Noel, J N Allen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancerJ E Berchuck, F Facchinetti, D F DiToro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinomaL Goyal, D DiToro, F Facchinetti, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2024
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profilingL Goyal, D DiToro, A Hollebecque, et al.
Acta Endocrinologica (Bucharest, Romania : 2005)|February 15, 2024
PHEOCHROMOCYTOMA, THE GREAT MASQUERADER, PRESENTING AS REVERSIBLE CARDIOMYOPATHY: <i>PRIMUM NON NOCERE</i>H Boro, H Sharma, D Mittal, et al.
ESMO Open|March 18, 2026
Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301G K Abou-Alfa, I Borbath, S Roychowdhury, et al.
British Journal of Cancer|June 25, 2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancerA F Hezel, M S Noel, J N Allen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancerJ E Berchuck, F Facchinetti, D F DiToro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinomaL Goyal, D DiToro, F Facchinetti, et al.
Pageof 6